AI-Generated Summary

The Indian Pharmaceutical Alliance (IPA) clarified that former President Trump's proposed 100% import tariff on pharmaceuticals will apply only to patented and branded drugs, not generics. This distinction suggests a limited immediate impact on India's pharmaceutical exports, which primarily consist of generics, with many Indian firms already having US manufacturing presence. The industry is advised to prepare for future policy shifts and explore advanced pharmaceutical opportunities.

In a nutshell

This clarification offers crucial insight into the specific targeting of proposed trade policies, underscoring the complex interplay between government initiatives and global pharmaceutical supply chains, particularly for generic medications essential to healthcare affordability.

Source: The Economic Times